Personalis Announces Delivery of the 100,000th Genome to the U.S. Department of Veterans Affairs Million Veteran Program
10 12월 2020 - 6:07AM
Business Wire
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics
for population sequencing and cancer, announced today that it has
delivered the 100,000th whole human genome sequence dataset to the
U.S. Department of Veterans Affairs Million Veteran Program (VA
MVP). Although Personalis has been contracted by the VA MVP since
2012, the program has accelerated and over 50,000 of these genomes
have been delivered in 2020.
“The VA MVP is the largest whole genome sequencing project in
the United States and this is a significant milestone for both the
program and for Personalis,” said John West, Chief Executive
Officer. “Population-scale sequencing projects of this nature
represent a cornerstone in our effort to accelerate the advancement
of precision medicine across a wide range of disease areas. With
our sizable investments in the technology and infrastructure,
necessary to win and execute these projects, Personalis sees
population genomics and health as key priorities for our company.
We congratulate the VA MVP for their visionary leadership and note
that VA scientists now list over 50 peer reviewed publications from
the Program.”
Earlier this year, the company strengthened its commitment to
this application area with the appointment of Mr. Kevin Dunne as
its Head of Population Genomics. Personalis believes the population
genomics research efforts of today will enable precision medicine
in healthcare systems, spanning both germline disease risk and
cancer management.
About the VA Million Veteran Program
Launched in 2011, the VA MVP is a landmark research effort aimed
at better understanding how genetic variations affect health. Up to
two-million veterans are expected to enroll in the VA MVP. Data and
genetic samples collected through the program are stored securely
and made available for studies by authorized researchers, with
stringent safeguards in place to protect Veterans’ private health
information. The VA MVP was enrolling veterans at 63 VA medical
centers nationwide prior to the pandemic. The VA’s central
biorepository is equipped with a state-of-the-art robotic system
for DNA extraction and storage and is currently being expanded to
support up to 4 million samples. With approximately 850,000
enrollees since 2011, the VA MVP already far exceeds the enrollment
numbers of any single VA study or research program in the past, and
is in fact one of the largest research cohorts of its kind in the
world. The VA MVP provides researchers with a rich resource of
genetic, health, lifestyle, and military-exposure data collected
from questionnaires, medical records, and genetic analyses. By
combining this information into a single database, the VA MVP
promises to advance knowledge about the complex links between genes
and health. Veterans’ privacy and confidentiality are top
priorities in the VA MVP, as in all VA research. For more
information about the VA MVP, visit www.research.va.gov/MVP. This
press release does not imply a Department of Veterans Affairs
endorsement, and is neither paid for nor sponsored, in whole or in
part, by any element of the United States government.
About Personalis, Inc.
Personalis, Inc. is a leader in population sequencing and cancer
genomics, with a focus on data, scale, efficiency and quality.
Personalis operates one of the largest sequencing operations
globally and is currently the sole sequencing provider to the VA
MVP. In oncology, Personalis is transforming the development of
next-generation therapies by providing more comprehensive molecular
data about each patient’s cancer and immune response. The
Personalis® ImmunoID NeXT Platform® is designed to adapt to the
complex and evolving understanding of cancer, providing its
biopharmaceutical customers with information on all of the
approximately 20,000 human genes, together with the immune system,
from a single tissue sample. The Personalis Clinical Laboratory is
GxP-aligned as well as CLIA’88-certified and CAP-accredited. For
more information, please visit www.personalis.com and follow
Personalis on Twitter (@PersonalisInc).
Forward-Looking Statements
All statements in this press release that are not historical are
“forward-looking statements” within the meaning of U.S. securities
laws, including statements relating to attributes or advantages of
the ImmunoID NeXT Platform, Personalis’ services for the VA MVP
(including continued receipt of VA MVP samples and continued
laboratory operations at the company), the company’s business
opportunities, leadership or growth, or other future events. Such
forward-looking statements involve risks and uncertainties,
including those related to the COVID-19 pandemic, that could cause
actual results to differ materially from any anticipated results or
expectations expressed or implied by such statements. Factors that
could materially affect actual results can be found in Personalis’
filings with the U.S. Securities and Exchange Commission, including
the company’s most recent reports on Forms 8-K, 10-K and 10-Q, and
include those listed under the caption “Risk Factors.” Personalis
disclaims any obligation to update such forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201209005963/en/
Investor Relations Contact: Caroline Corner
investors@personalis.com 415-202-5678 Media Contact: Jennifer
Havlek pr@personalis.com www.personalis.com 650-752-1300
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024